South San Francisco, CA July 12, 2022 Genentech Press Release New Data From Phase III Haven 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People with Moderate or Mild Hemophilia A Hemlibra continues to…